Physician profile
Ken C Lin
NPI 1124169636
$4,005.22
in general payments reported to CMS, 2019-2025
23 companies · $652 in 2025
The $652 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $479 · 2021: $530 · 2022: $348 · 2023: $567 · 2024: $719 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $431.77 | 2019-2025 | Cequa, Xelpros |
| Alcon Vision LLC | $317.81 | 2019-2025 | Rocklatan, Tryptyr, Hydrus Microstent |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $317.23 | 2019-2021 | |
| Abbvie INC. | $298.74 | 2022-2025 | |
| Amgen INC. | $294.71 | 2024-2025 | Tepezza |
| Allergan, INC. | $278.53 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $233.46 | 2019-2021 | |
| Dompe US, INC. | $198.50 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $196.57 | 2019-2023 | |
| Oyster Point Pharma, INC. | $175.23 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $172.13 | 2022-2025 | Vyzulta, Miebo, Envista Envy Iol |
| Tarsus Pharmaceuticals, INC. | $169.13 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $157.88 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $154.57 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $148.03 | 2024-2025 | Acthar |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $133.93 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $112.36 | 2020-2025 | Acuvue |
| Shire North American Group INC | $60.72 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $47.93 | 2022 | |
| Sight Sciences, INC. | $32.49 | 2021 | |
| Biotissue Holdings INC. | $28.22 | 2025 | |
| Harrow Eye, LLC | $25.88 | 2025 | Vevye |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ken Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.